These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35176116)

  • 1. Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing.
    van der Meulen MP; Toes-Zoutendijk E; Spaander MCW; Dekker E; Bonfrer JMG; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; van Velthuysen MF; Thomeer MGJ; van Veldhuizen H; de Koning HJ; Lansdorp-Vogelaar I; van Leerdam ME
    PLoS One; 2022; 17(2):e0264067. PubMed ID: 35176116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
    Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
    Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands.
    de Klerk CM; van der Vlugt M; Smagge BA; Toes-Zoutendijk E; Lansdorp-Vogelaar I; Dekker E; Bossuyt PM
    Prev Med Rep; 2022 Jun; 27():101791. PubMed ID: 35656204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round.
    Stegeman I; de Wijkerslooth TR; Mallant-Hent RC; de Groot K; Stroobants AK; Fockens P; Mundt M; Bossuyt PM; Dekker E
    BMC Gastroenterol; 2012 Jun; 12():73. PubMed ID: 22713100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme.
    Kortlever TL; van der Vlugt M; Duijkers FAM; Masclee A; Kraaijenhagen R; Spaander MCW; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E
    Br J Cancer; 2023 Sep; 129(5):791-796. PubMed ID: 37468570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial.
    Stoop EM; de Haan MC; de Wijkerslooth TR; Bossuyt PM; van Ballegooijen M; Nio CY; van de Vijver MJ; Biermann K; Thomeer M; van Leerdam ME; Fockens P; Stoker J; Kuipers EJ; Dekker E
    Lancet Oncol; 2012 Jan; 13(1):55-64. PubMed ID: 22088831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
    Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
    Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Essink-Bot ML; Spaander MC; Dekker E
    Br J Cancer; 2017 Jan; 116(1):44-49. PubMed ID: 27923037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme.
    van de Schootbrugge-Vandermeer HJ; Lansdorp-Vogelaar I; de Jonge L; van Vuuren AJ; Dekker E; Spaander MCW; Ramakers CRB; Nagtegaal ID; van Kemenade FJ; van Leerdam ME; Toes-Zoutendijk E
    Eur J Cancer; 2023 Sep; 190():112942. PubMed ID: 37406529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.